Research Analysts Set Expectations for SABS Q2 Earnings

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Research analysts at Brookline Capital Markets issued their Q2 2026 earnings per share estimates for SAB Biotherapeutics in a report issued on Friday, May 15th. Brookline Capital Markets analyst K. Raja expects that the company will earn ($0.25) per share for the quarter. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($1.22) per share.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15).

A number of other brokerages have also recently weighed in on SABS. HC Wainwright boosted their price objective on SAB Biotherapeutics from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Wall Street Zen cut SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. Rodman & Renshaw reiterated a “buy” rating and issued a $13.00 price objective on shares of SAB Biotherapeutics in a research note on Monday, May 11th. Zacks Research upgraded SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of SAB Biotherapeutics in a research note on Friday, April 10th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $11.00.

SAB Biotherapeutics Price Performance

Shares of NASDAQ SABS opened at $3.56 on Tuesday. The company has a current ratio of 11.45, a quick ratio of 11.45 and a debt-to-equity ratio of 0.01. SAB Biotherapeutics has a twelve month low of $1.60 and a twelve month high of $6.60. The stock has a 50 day moving average of $3.85 and a two-hundred day moving average of $3.83. The stock has a market cap of $181.39 million, a P/E ratio of -1.69 and a beta of 0.55.

Institutional Investors Weigh In On SAB Biotherapeutics

Large investors have recently modified their holdings of the stock. PNC Financial Services Group Inc. purchased a new stake in shares of SAB Biotherapeutics during the first quarter worth approximately $29,000. ADAR1 Capital Management LLC purchased a new stake in shares of SAB Biotherapeutics during the third quarter worth approximately $30,000. Dimensional Fund Advisors LP purchased a new position in SAB Biotherapeutics in the third quarter worth $32,000. State of Wyoming purchased a new position in SAB Biotherapeutics in the fourth quarter worth $34,000. Finally, Virtu Financial LLC purchased a new position in SAB Biotherapeutics in the third quarter worth $40,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.